HDAC6 and cancer: Currently, there are no FDA-approved HDAC6 inhibitors; however, the selective HDAC6 inhibitor ACY-1215 has shown potential in numerous phase I and II clinical trials with current investigation into use in combinatorial cancer treatment.53